Crescita Therapeutics Inc. (CTX.TO)

CAD 0.57

(1.79%)

EBITDA Summary of Crescita Therapeutics Inc.

  • Crescita Therapeutics Inc.'s latest annual EBITDA in 2023 was 45 Thousand CAD , down -120.43% from previous year.
  • Crescita Therapeutics Inc.'s latest quarterly EBITDA in 2024 Q1 was -346 Thousand CAD , down -180.45% from previous quarter.
  • Crescita Therapeutics Inc. reported an annual EBITDA of 2.09 Million CAD in 2022, up 159.18% from previous year.
  • Crescita Therapeutics Inc. reported an annual EBITDA of 598 Thousand CAD in 2021, down -78.78% from previous year.
  • Crescita Therapeutics Inc. reported a quarterly EBITDA of -346 Thousand CAD for 2024 Q1, down -180.45% from previous quarter.
  • Crescita Therapeutics Inc. reported a quarterly EBITDA of 266 Thousand CAD for 2023 Q4, up 130.16% from previous quarter.

Annual EBITDA Chart of Crescita Therapeutics Inc. (2023 - 2014)

Historical Annual EBITDA of Crescita Therapeutics Inc. (2023 - 2014)

Year EBITDA EBITDA Growth
2023 45 Thousand CAD -120.43%
2022 2.09 Million CAD 159.18%
2021 598 Thousand CAD -78.78%
2020 2.26 Million CAD -29.72%
2019 5.58 Million CAD 240.44%
2018 2.39 Million CAD 133.72%
2017 -9.65 Million CAD 64.61%
2016 -14.42 Million CAD 8.46%
2015 -7.38 Million CAD -16.29%
2014 -14.24 Million CAD 0.0%

Peer EBITDA Comparison of Crescita Therapeutics Inc.

Name EBITDA EBITDA Difference
Aurora Cannabis Inc. 20.47 Million CAD 99.78%
Avicanna Inc. -7.35 Million CAD 100.612%
Avant Brands Inc. 4.83 Million CAD 99.069%
Cardiol Therapeutics Inc. -27.87 Million CAD 100.161%
Knight Therapeutics Inc. 40.89 Million CAD 99.89%
MediPharm Labs Corp. -10.47 Million CAD 100.429%
OrganiGram Holdings Inc. -207.61 Million CAD 100.022%
Canopy Growth Corporation -312.82 Million CAD 100.014%
Willow Biosciences Inc. -11.06 Million CAD 100.407%
Auxly Cannabis Group Inc. -10.82 Million CAD 100.416%